Description
Seeking adults aged 18 to 65 with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS) for a study of an investigational formulation of the drug Ocrelizumab.
Overview
Participants will initially get a dose of either the usual or the investigational formulation of Ocrelizumab as one injection. After 6 months all participants will get the investigational formulation injection every six months for 2.5 years. There will be a total of 27 study visits over 3.5 years.
What we're hoping for
We are studying if a new formulation of the drug Ocrelizumab is used by the body in the same way as the standard formulation for people aged 18 to 65 with relapsing or primary progression multiple sclerosis.
Additional Information
ClinicalTrials.gov Identifier: NCT07074886